OCGN Stock Analysis: Buy, Sell, or Hold?
OCGN - Ocugen, Inc. Common Stock
$1.36
-0.01 (-0.73%)
▼
5d:
-7.48%
30d:
+15.25%
90d:
-29.53%
HOLD
LOW Confidence
Analysis Updated: Jul 17, 2026 12:00 AM ET
Earnings: Aug 07, 2026
19d
Get Alerted When OCGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: OCGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: OCGN shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: OCGN is currently trading at $1.36, which is considered fair relative to its 30-day fair value range of $1.25 to $1.50. From a valuation perspective, the stock is trading at a discount (Forward PE: -5.8) compared to its historical average (40.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, OCGN is in a strong downtrend. The price is currently testing key support at $1.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.43 (+740.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, OCGN is in a strong downtrend. The price is currently testing key support at $1.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.43 (+740.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.25 -
$1.50
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.1%
Protect Your Profits
Holding OCGN? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 740.3% below Wall St target ($11.43)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- CAUTION: Recommendation downgraded due to -7.5% 5-day decline
Trading Range Analysis
30-Day Trading Range
$1.25 -
$1.50
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.34
Resistance Level
$1.53
Current Trend
Strong Downtrend
Technical data as of
Jul 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.79
Wall Street Target
$11.43
(+740.3%)
Revenue Growth (YoY)
3.5%
PE vs Historical
-5.8 vs 40.6
CHEAP
Share & Embed Analysis
Last updated: July 18, 2026 5:26 PM ET
Data refreshes hourly during market hours. Next update: 6:26 PM
Data refreshes hourly during market hours. Next update: 6:26 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OCGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 47 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 66 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 50 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$124 | 58 HOLD |
Advanced OCGN Option Strategies
Professional options setups generated by AI based on today's OCGN price and gamma walls.
